American Journal of Respiratory Medicine

, Volume 2, Issue 1, pp 39–54 | Cite as

Optimizing Treatment Outcomes in Severe Community-Acquired Pneumonia

Therapy In Practice


Severe community-acquired pneumonia (CAP) is a life-threatening condition that requires intensive care unit (ICU) admission. Clinical presentation is characterized by the presence of respiratory failure, severe sepsis, or septic shock. Severe CAP accounts for approximately 5–35% of hospital-treated cases of pneumonia with the majority of patients having underlying comorbidities. The most common pathogens associated with this disease are Streptococcus pneumoniae, Legionella spp., Haemophilus influenzae, and Gram-negative enteric rods.

Microbial investigation is probably helpful in the individual case but is likely to be more useful for defining local antimicrobial policies. The early and rapid initiation of empiric antimicrobial treatment is critical for a favorable outcome. It should include intravenous β-lactam along with either a macrolide or a fluoroquinolone. Modifications of this basic regimen should be considered in the presence of distinct comorbid conditions and risk factors for specific pathogens. Other promising nonantimicrobial new therapies are currently being investigated.

The assessment of severity of CAP helps physicians to identify patients who could be managed safely in an ambulatory setting. It may also play a crucial role in decisions about length of hospital stay and time of switching to oral antimicrobial therapy in different groups at risk. The most important adverse prognostic factors include advancing age, male sex, poor health of patient, acute respiratory failure, severe sepsis, septic shock, progressive radiographic course, bacteremia, signs of disease progression within the first 48–72 hours, and the presence of several different pathogens such as S. pneumoniae, Staphylococcus aureus, Gram-negative enteric bacilli, or Pseudomonas aeruginosa. However, some important topics of severity assessment remain controversial, including the definition of severe CAP. Prediction rules for complications or death from CAP, although far from perfect, should identify the majority of patients with severe CAP and be used to support decision-making by the physician. They may also contribute to the evaluation of processes and outcomes of care for patients with CAP.



The authors have provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review.


  1. 1.
    Marston BJ, Plouffe JF, File TM, et al. Incidence of community-acquired pneumonia requiring hospitalization. Arch Intern Med 1997; 157: 1709–18PubMedGoogle Scholar
  2. 2.
    National Center for Health Statistics. National Hospital Discharge Survey: annual summary 1990. Vital Health Stat 13 1992; 113: 1–225Google Scholar
  3. 3.
    National Center for Health Statistics. Health United States, 2000 with adolescent health Chartbook. Hyattsville (MD): National Center for Health Statistics, 2000: 177Google Scholar
  4. 4.
    Pachón J, Prados MD, Capote F, et al. Severe community-acquired pneumonia. Etiology, prognosis and treatment. Am Rev Respir Dis 1990; 142: 369–73PubMedGoogle Scholar
  5. 5.
    Feldman C, Ross S, Goolam MA, et al. The aetiology of severe community-acquired pneumonia and its impact on initial empiric antimicrobial therapy. Respir Med 1995; 89: 187–92PubMedGoogle Scholar
  6. 6.
    Moine P, Vercken JP, Chevret S, et al. Severe community-acquired pneumonia: etiology, epidemiology and prognosis factors. Chest 1994; 105: 1487–95PubMedGoogle Scholar
  7. 7.
    Leroy O, Santré C, Beuscart C, et al. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med 1995; 21: 24–31PubMedGoogle Scholar
  8. 8.
    Research Committee of the British Thoracic Society and the Public Health Laboratory Service. Community-acquired pneumonia in adults in British hospitals in 1982–83: a survey of aetiology, mortality, prognostic factors and outcome. Q J Med 1987; 62: 195–220Google Scholar
  9. 9.
    Farr BM, Sloman AJ, Fisch MJ. Predicting death in patients hospitalized for community-acquired pneumonia. Ann Intern Med 1991; 115: 428–36PubMedGoogle Scholar
  10. 10.
    Neill AM, Martin IR, Weir R, et al. Community-acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996; 51: 1010–6PubMedGoogle Scholar
  11. 11.
    American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418–26Google Scholar
  12. 12.
    Ewig S, Ruiz M, Mensa J, et al. Severe community-acquired pneumonia: assessment of severity criteria. Am J Respir Crit Care Med 1998; 158: 1102–8PubMedGoogle Scholar
  13. 13.
    Gordon GS, Throop D, Berberian L, et al. Validation of the American Thoracic Society (ATS) guidelines for community-acquired pneumonia in hospitalized patients [abstract]. Am J Respir Crit Care Med 1996; 153: A257Google Scholar
  14. 14.
    American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730–54Google Scholar
  15. 15.
    Vallés J. Severe pneumonia: sources of infection and implications for prevention. Sepsis 1998; 1: 199–209Google Scholar
  16. 16.
    Woodhead MA, Macfarlane JT, Rodgers FG, et al. Aetiology and outcome of severe community-acquired pneumonia. J Infect 1985; 10: 204–10PubMedGoogle Scholar
  17. 17.
    Lim WS, Macfarlane JT, Boswell TC, et al. Study of community-acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001; 56: 296–301PubMedGoogle Scholar
  18. 18.
    Rosón B, Carratalá J, Dorca J, et al. Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin Infect Dis 2001; 33: 158–65PubMedGoogle Scholar
  19. 19.
    Torres A, Serra-Batlles J, Ferrer A, et al. Severe community-acquired pneumonia: epidemiology and prognostic factors. Am Rev Respir Dis 1991; 144: 312–8PubMedGoogle Scholar
  20. 20.
    Ruiz M, Ewig S, Torres A, et al. Severe community-acquired pneumonia: risk factors and follow-up epidemiology. Am J Respir Crit Care Med 1999; 160: 923–9PubMedGoogle Scholar
  21. 21.
    Chien JW, Johnson JL. Viral pneumonias: epidemic respiratory viruses. Postgrad Med 2000; 107(3): 41–52PubMedGoogle Scholar
  22. 22.
    Georges H, Leroy O, Vandenbussche C, et al. Epidemiological features and prognosis of severe community-acquired pneumococcal pneumonia. Intensive Care Med 1999; 25: 198–206PubMedGoogle Scholar
  23. 23.
    Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343: 1917–24PubMedGoogle Scholar
  24. 24.
    Moroney JF, Fiore AE, Harrison LH, et al. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis 2001; 33: 797–805PubMedGoogle Scholar
  25. 25.
    Kalin M, Ortqvist A, Almela M, et al. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis 2000; 182: 840–7PubMedGoogle Scholar
  26. 26.
    Metlay JP, Hofmann J, Cetron MS, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000; 30: 520–8PubMedGoogle Scholar
  27. 27.
    El-Ebiary M, Sarmiento X, Torres A, et al. Prognostic factors of severe Legionella pneumonia requiring admission to ICU. Am J Respir Crit Care Med 1997; 156: 1467–72PubMedGoogle Scholar
  28. 28.
    Rello J, Rodríguez R, Jubert P, et al. Severe community-acquired pneumonia in the elderly: epidemiology and prognosis. Clin Infect Dis 1996; 23: 723–8PubMedGoogle Scholar
  29. 29.
    Ruiz M, Ewig S, Marcos MA, et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 1999; 160: 397–405PubMedGoogle Scholar
  30. 30.
    Olaechea PM, Quintana JM, Gallardo MS, et al. A predictive model for the treatment approach to community-acquired pneumonia in patients needing ICU admission. Intensive Care Med 1996; 22: 1294–300PubMedGoogle Scholar
  31. 31.
    Hirani NA, Macfarlane JT. Impact of management guidelines on the outcome of severe community acquired pneumonia. Thorax 1997; 52: 17–21PubMedGoogle Scholar
  32. 32.
    Rello J, Quintana E, Ausina V, et al. Risks factors for Staphylococcus aureus nosocomial pneumonia in critically ill patients. Am Rev Respir Dis 1990; 142: 1320–4PubMedGoogle Scholar
  33. 33.
    El-Solh AA, Sikka P, Ramadan F, et al. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med 2001; 163: 645–51PubMedGoogle Scholar
  34. 34.
    Menéndez R, Córdoba J, de la Cuadra P, et al. Value of the polymerase chain reaction assay in noninvasive respiratory samples for diagnosis of community-acquired pneumonia. Am J Respir Crit Care Med 1999; 159: 1868–73PubMedGoogle Scholar
  35. 35.
    Ruiz A, Falguera M, Nogués A, et al. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology?.: a microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med 1999; 106: 385–90Google Scholar
  36. 36.
    Celis MR, Torres A, Zalacain R, et al. Study on diagnostic methods and treatment of community-acquired pneumonia in Spain [in Spanish]. Med Clin (Barc) 2002; 119(9): 321–6Google Scholar
  37. 37.
    Sanyal S, Smith PR, Saha AC, et al. Initial microbiologie studies did not affect outcome in adults hospitalized with community-acquired pneumonia. Am J Respir Crit Care Med 1999; 160: 346–8PubMedGoogle Scholar
  38. 38.
    Waterer GW, Wunderink RG. The impact of severity on the utility of blood cultures in community-acquired pneumonia. Respir Med 2001; 95: 78–82PubMedGoogle Scholar
  39. 39.
    Niederman MS. Severe community-acquired pneumonia: what do we need to know to effectively manage patients? Intensive Care Med 1996; 22: 1285–7PubMedGoogle Scholar
  40. 40.
    Gupta SK, Imperiale TF, Sarosi GA. Evaluation of the Winthrop-University Hospital criteria to identify Legionella pneumonia. Chest 2001; 120: 1064–71PubMedGoogle Scholar
  41. 41.
    Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. JAMA 1996; 275: 134–41PubMedGoogle Scholar
  42. 42.
    Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process and outcomes in elderly patients with pneumonia. JAMA 1997; 278: 2080–4PubMedGoogle Scholar
  43. 43.
    Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 1993; 137: 977–88PubMedGoogle Scholar
  44. 44.
    Koviula I, Sten M, Makela PH. Risk factors for pneumonia in the elderly. Am J Med 1994; 96: 313–20Google Scholar
  45. 45.
    Almirall J, Mesalles E, Klamburg J, et al. Prognostic factors of pneumonia requiring admission to the intensive care unit. Chest 1995; 107: 511–6PubMedGoogle Scholar
  46. 46.
    British Thoracic Society Research Committee and The Public Health Laboratory Service. The aetiology, management and outcome of severe community-acquired pneumonia on the intensive care unit. Respir Med 1992; 86: 7–13Google Scholar
  47. 47.
    Fine MJ, Smith DN, Singer DE. Hospitalization decision in patients with community-acquired pneumonia: a prospective cohort study. Am J Med 1990; 89: 713–21PubMedGoogle Scholar
  48. 48.
    Riquelme R, Torres A, El-Ebiary M, et al. Community-acquired pneumonia in the elderly: a multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med 1996; 154: 1450–5PubMedGoogle Scholar
  49. 49.
    Fernández-Sola J, Junque A, Estruch R, et al. High alcohol intake as a risk and prognostic factor for community-acquired pneumonia. Arch Intern Med 1995; 155: 1649–54PubMedGoogle Scholar
  50. 50.
    Yee AMF, Phan HM, Zuniga R, et al. Association between FcγRIIa-R131 allotype and bacteremic pneumococcal pneumonia. Clin Infect Dis 2000; 30: 25–8PubMedGoogle Scholar
  51. 51.
    Ewig S, Bauer T, Hasper E, et al. Prognostic analysis and predictive rule for outcome of hospital-treated community-acquired pneumonia. Eur Respir J 1995; 8: 392–7PubMedGoogle Scholar
  52. 52.
    Álvarez B, Álvarez-Lerma F, Jordá R, et al. Prognostic factors and etiology in patients with severe community-acquired pneumonia admitted at the ICU. Spanish multicenter study: study group on severe community-acquired pneumonia in Spain [in Spanish]. Med Clin (Barc) 1998; 111: 650–4Google Scholar
  53. 53.
    Örtqvist A, Hedlund J, Grillner L, et al. Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalisation. Eur Respir J 1990; 3: 1105–13PubMedGoogle Scholar
  54. 54.
    Leroy O, Devos P, Guery B, et al. Simplified prediction rule for prognosis of patients with severe community-acquired pneumonia in ICUs. Chest 1999; 116: 157–65PubMedGoogle Scholar
  55. 55.
    Woodhead MA, Radvan J, Macfarlane JT. Adult community-acquired staphylococcal pneumonia in the antibiotic era: a review of 61 cases. Q J Med 1987; 245: 783–90Google Scholar
  56. 56.
    Jong GM, Hsiue TR, Chen CR, et al. Rapidly fatal outcome of bacteremic Klebsiella pneumoniae pneumonia in alcoholics. Chest 1995; 107: 214–7PubMedGoogle Scholar
  57. 57.
    Black ER, Mushlin AI, Griner PF, et al. Predicting the need for hospitalization of ambulatory patients with pneumonia. J Gen Intern Med 1991; 6: 394–400PubMedGoogle Scholar
  58. 58.
    Ewig S, Schäfer H, Torres A. Severity assessment in community-acquired pneumonia. Eur Respir J 2000; 16: 1193–201PubMedGoogle Scholar
  59. 59.
    Ewig S. Community-acquired pneumonia: epidemiology, risk, and prognosis. Eur Respir Mon 1997; 3: 13–35Google Scholar
  60. 60.
    Nelson S, Manson CM, Kolls J, et al. Pathophysiology of pneumonia. Clin Chest Med 1995; 16: 1–12PubMedGoogle Scholar
  61. 61.
    Ewig S, Torres A. Severe community-acquired pneumonia: what might be done better. Intensive Care Med 1999; 25: 143–5PubMedGoogle Scholar
  62. 62.
    Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. N Engl J Med 2000; 342: 681–9PubMedGoogle Scholar
  63. 63.
    Waterer GW, Quasney MW, Cantor RM, et al. Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med 2001; 163: 1599–604PubMedGoogle Scholar
  64. 64.
    Leroy O, Georges H, Beuscart C, et al. Severe community-acquired pneumonia in ICUs: prospective validation of a prognostic score. Intensive Care Med 1996; 22: 1307–14PubMedGoogle Scholar
  65. 65.
    Potgieter PD, Hammond JMJ. The intensive care management, mortality and prognostic indicators in severe community-acquired pneumonia. Intensive Care Med 1996; 22: 1301–6PubMedGoogle Scholar
  66. 66.
    Moine P, Vercken JB, Chevret S, et al. Severe community-acquired pneumococcal pneumonia. Scand J Infect Dis 1995; 27: 201–6PubMedGoogle Scholar
  67. 67.
    Fine MJ, Singer DE, Hanusa BH, et al. Validation of a pneumonia prognostic index using the MedisGroups Comparative Hospital Database. Am J Med 1993; 94: 153–9PubMedGoogle Scholar
  68. 68.
    Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243–50PubMedGoogle Scholar
  69. 69.
    Ewig S, Kleinfield T, Bauer T, et al. Comparative validation of prognostic rules for community-acquired pneumonia in the elderly. Eur Respir J 1999; 14: 370–5PubMedGoogle Scholar
  70. 70.
    Mylotte JM, Naughton B, Saludades C, et al. Validation and application of the pneumonia prognosis index to nursing home residents with pneumonia. J Am Geriatr Soc 1998; 46: 1538–44PubMedGoogle Scholar
  71. 71.
    Atlas SJ, Benzer TI, Borowsky LH, et al. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients. Arch Intern Med 1998; 158: 1350–6PubMedGoogle Scholar
  72. 72.
    Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA 2000; 283: 749–55PubMedGoogle Scholar
  73. 73.
    Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998; 279: 1452–7PubMedGoogle Scholar
  74. 74.
    Lim WS, Lewis S, Macfarlane JT. Severity prediction rules in community-acquired pneumonia: a validation study. Thorax 2000; 55: 219–23PubMedGoogle Scholar
  75. 75.
    Pascual FE, Matthay MA, Bacchetti P, et al. Assessment of prognosis in patients with community-acquired pneumonia who require mechanical ventilation. Chest 2000; 117:503–12PubMedGoogle Scholar
  76. 76.
    Mehta R, Groth M. Clinical application of a prognostic model for severe community-acquired pneumonia [letter]. Chest 2001; 119: 312–3PubMedGoogle Scholar
  77. 77.
    Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347–82PubMedGoogle Scholar
  78. 78.
    Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000; 31: 383–421PubMedGoogle Scholar
  79. 79.
    British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults. Thorax 2001; 56Suppl. IV: iv1–64Google Scholar
  80. 80.
    Burgess DS, Lewis II JS. Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. Clin Ther 2000; 22: 872–8PubMedGoogle Scholar
  81. 81.
    Gleason PP, Meehan TP, Fine JM, et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159: 2562–72PubMedGoogle Scholar
  82. 82.
    Houck PM, MacLehose RF, Niederman MS, et al. Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states 1993, 1995, and 1997. Chest 2001; 119: 1420–6PubMedGoogle Scholar
  83. 83.
    Jones ME, Sahm DF, Martin N, et al. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance during the 1997–1998 respiratory season. Antimicrob Agents Chemother 2000; 44: 462–6PubMedGoogle Scholar
  84. 84.
    Chen DK, McGeer A, de Azavedo JC, et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341: 233–9PubMedGoogle Scholar
  85. 85.
    Barry AL, Brown SD, Fuchs PC. Fluoroquinolone resistance among recent clinical isolates of Streptococcus pneumoniae. J Antimicrob Chemother 1999; 43: 428–9PubMedGoogle Scholar
  86. 86.
    Ho PL, Que TL, Tsang DN, et al. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1999; 43: 1310–3PubMedGoogle Scholar
  87. 87.
    Ho LP, Tse WS, Tsang KWT, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis 2001; 32: 701–7PubMedGoogle Scholar
  88. 88.
    Chen MZ, Hsueh PR, Lee LN, et al. Severe community-acquired pneumonia due to Acinetobacter baumanii. Chest 2001; 120: 1072–7PubMedGoogle Scholar
  89. 89.
    Wunderink RG, Waterer GW. Severe community-acquired pneumonia: the need to customize empiric therapy. Chest 2001; 120: 1053–5PubMedGoogle Scholar
  90. 90.
    Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161: 1837–42PubMedGoogle Scholar
  91. 91.
    Ramirez JA, Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia. Arch Intern Med 2001; 161: 848–50PubMedGoogle Scholar
  92. 92.
    Rhew DC, Tu GS, Ofman J, et al. Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis. Arch Intern Med 2001; 161: 722–7PubMedGoogle Scholar
  93. 93.
    Arancibia F, Ewig S, Martínez JA, et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med 2000; 162: 154–60PubMedGoogle Scholar
  94. 94.
    Confalonieri M, Potena A, Carbone G, et al. Acute respiratory failure in patients with severe community-acquired pneumonia: a prospective randomized evaluation of noninvasive ventilation. Am J Respir Crit Care Med 1999; 160: 1585–91PubMedGoogle Scholar
  95. 95.
    Navalesi P, Pollini A. Acute respiratory failure in patients with severe community-acquired pneumonia: a prospective randomized evaluation of noninvasive ventilation [letter]. Am J Respir Crit Care Med 2000; 162: 761–2PubMedGoogle Scholar
  96. 96.
    Hilbert G, Gruson D, Vargas F, et al. Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. N Engl J Med 2001; 344: 481–7PubMedGoogle Scholar
  97. 97.
    Jolliet P, Abajo B, Pasquina P, et al. Non-invasive pressure support ventilation in severe community-acquired pneumonia. Intensive Care Med 2001; 27: 812–21PubMedGoogle Scholar
  98. 98.
    Dreyfuss D, Djedaini K, Lanore JJ, et al. A comparative study of the effects of almitrine bimesylate and lateral position during unilateral bacterial pneumonia with severe hypoxemia. Am Rev Respir Dis 1992; 146: 295–9PubMedGoogle Scholar
  99. 99.
    Gea J, Roca J, Torres A, et al. Mechanisms of abnormal gas exchange in patients with pneumonia. Anesthesiology 1991; 75: 782–9PubMedGoogle Scholar
  100. 100.
    Rodríguez-Roisín R, Roca J. Update’ 96 on pulmonary gas exchange pathophysiology in pneumonia. Semin Respir Infect 1996; 11: 3–12PubMedGoogle Scholar
  101. 101.
    Hanly PJ, Roberts D, Dobson K, et al. Effect of indomethacin on arterial oxygenation in critically ill patients with severe bacterial pneumonia. Lancet 1987; I: 351–4Google Scholar
  102. 102.
    Ferrer M, Torres A, Baer R, et al. Effect of acetylsalicylic acid on pulmonary gas exchange in patients with severe pneumonia: a pilot study. Chest 1997; 111: 1094–100PubMedGoogle Scholar
  103. 103.
    Walmrath D, Schneider T, Pilch J, et al. Effects of aerosolized prostacyclin in severe pneumonia: impact of fibrosis. Am J Respir Crit Care Med 1995; 151: 724–30PubMedGoogle Scholar
  104. 104.
    Rossaint R, Falke KJ, López F, et al. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993; 328: 399–405PubMedGoogle Scholar
  105. 105.
    Gómez FP, Iglesia R, Torres A, et al. Nitric oxide inhalation in severe pneumonia [abstract]. Eur Respir J 1997; 10Suppl. 25: 21sGoogle Scholar
  106. 106.
    Bauer TT, Montón C, Torres A, et al. Comparison of systemic cytokine levels in patients with acute respiratory distress syndrome, severe pneumonia, and controls. Thorax 2000; 55: 46–52PubMedGoogle Scholar
  107. 107.
    Nelson S, Bagby GJ, Bainton BG, et al. Compartmentalization of intraalveolar and systemic lipopolysaccharide-induced tumor necrosis factor and the pulmonary inflammatory response. J Infect Dis 1989; 159: 189–94PubMedGoogle Scholar
  108. 108.
    Wunderink RG, Leeper KV, Schein R, et al. Filgrastim in patients with pneumonia and severe sepsis or septic shock. Chest 2001; 119: 523–9PubMedGoogle Scholar
  109. 109.
    Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699–709PubMedGoogle Scholar
  110. 110.
    Marik P, Kraus P, Sribante J, et al. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia: a randomized controlled study. Chest 1993; 104: 389–92PubMedGoogle Scholar
  111. 111.
    Montón C, Ewig S, Torres A, et al. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J 1999; 14: 218–20PubMedGoogle Scholar
  112. 112.
    Mer M, Richards GA. Corticosteroids in life-threatening varicella pneumonia. Chest 1998; 114: 426–31PubMedGoogle Scholar

Copyright information

© Adis International Limited 2003

Authors and Affiliations

  1. 1.Servicio de Neumología, Hospital Universitario de Gran Canaria “Dr. Negrín”Universidad de Las Palmas de Gran CanariaLas PalmasSpain
  2. 2.Institut Cliníc de Pneumologia i Cirurgia ToràcicaHospital Clínic de BarcelonaVillarroel, Barcelona, 170Spain

Personalised recommendations